To effectively treat the KRAS-mutant lung cancer, researchers have used many drugs, such as gefitinib, erlotinib, cisplatin, trametinib, and pazopanib (Kim et al., 2018; Pujol et al., 2006). Here, KRAS is linked to lung carcinoma.